Life Sciences

  • April 23, 2026

    Kirkland To Add Tenn. SG Behind Skrmetti Supreme Court Win

    The Tennessee solicitor general, who successfully defended the state's ban on some gender-affirming care for minors before the U.S. Supreme Court, will join the Nashville office of Kirkland & Ellis, the firm announced Thursday. 

  • April 23, 2026

    Firm Seeking Philly Zantac Judge's Recusal Appeals Refusal

    A plaintiff represented by Keller Postman LLC has asked the Pennsylvania Superior Court to weigh in on a Philadelphia judge's refusal to recuse himself from overseeing mass tort litigation against GlaxoSmithKline over Zantac's alleged cancer risks.

  • April 23, 2026

    ITC Investigating Chinese Biopharma Chemicals Over Pricing

    The U.S. International Trade Commission is looking into whether Chinese imports of two chemicals used in biopharma manufacturing that are allegedly being sold at unfair prices are harming U.S. domestic industry, it said in a notice published Thursday.

  • April 23, 2026

    DOJ Says Medical Pot Shift Shouldn't Affect Gun Rights Case

    Despite an order from the U.S. Department of Justice loosening federal restrictions on medical marijuana, the Trump administration signaled Thursday that it does not intend for the changes to cannabis regulation to apply retroactively.

  • April 23, 2026

    Trulieve Says Infringement Suit Doesn't Actually State A Claim

    Cannabis company Trulieve Inc. has said a rival company's complaint against it lacks any factual basis to support the allegation Trulieve infringed the rival's patents, urging a Florida federal court to throw out the suit.

  • April 23, 2026

    DOJ Final Order Loosens Rules For State-Legal Medical Pot

    The U.S. Department of Justice published a final order Thursday loosening federal restrictions on medical marijuana products that fall within the ambit of state-regulated programs or have approval from the U.S. Food and Drug Administration.

  • April 22, 2026

    Full Fed. Circ. Passes On Sarepta's Patent Rehearing Bid

    The full Federal Circuit on Wednesday rejected Sarepta Therapeutics Inc.'s bid for a rehearing after a panel's decision revived a University of Pennsylvania gene therapy patent that is licensed by clinical-stage biotechnology company Regenxbio Inc.

  • April 22, 2026

    Bayer 'Natural' Vitamin Buyer Classes Affirmed By 9th Circ.

    A split Ninth Circuit on Tuesday upheld a federal district court's certification of New York and California classes of consumers who bought Bayer Healthcare multivitamin gummies that were allegedly labeled falsely as "natural," finding the company "demands more" from the plaintiffs at this stage of the litigation than certification requires. 

  • April 22, 2026

    Eli Lilly Case Over Weight Loss Drugs Kept Mostly Intact

    A California federal court has refused to throw out a lawsuit from Eli Lilly against a telehealth company and related entities over the compounding of its popular weight loss drugs Mounjaro and Zepbound, but agreed to trim a conspiracy claim from the case.

  • April 22, 2026

    Justices Would Back Vax Law Challenge, 2nd Circ. Told

    The U.S. Supreme Court's March 2 decision in a California gender-related school policy case requires the Second Circuit to advance a 2023 challenge to Connecticut's preschool and daycare student vaccine mandates, an attorney for a Constitution State congregation told a three-judge panel on Wednesday.

  • April 22, 2026

    Judge Lets Pharma Co. Seal Parts Of Ex-GC's Retaliation Suit

    A Texas state judge on Wednesday granted Houston-based Empower Clinic Services LLC's bid to permanently and partially seal a petition by its former general counsel that alleges a smear campaign by the company after he confronted them about conduct he said was unlawful.

  • April 22, 2026

    Sorrento, M3 Get Pause On RICO Suit Naming Jackson Walker

    A Texas bankruptcy judge on Wednesday agreed to put on hold a lawsuit in California federal court alleging Jackson Walker LLP and executives at Sorrento Therapeutics and M3 Partners conspired to forum shop in Texas so the drug developer could seek Chapter 11 protection there.

  • April 22, 2026

    Oura Hit With New Patent Suit Over Fitness Wearables

    Zepp Health has hit Oura Health with a lawsuit in the Eastern District of Texas accusing the Finnish company of infringing a series of patents on wearable fitness devices, the latest salvo in a wider patent fight between the companies.

  • April 22, 2026

    Ex-Conn. Prosecutor Fights Drug Co. Bid To Appeal DQ Denial

    Insurers Humana Inc. and Molina Healthcare Inc. urged a federal judge to turn down a group of generic-drug makers' request for an immediate trip to the Third Circuit, arguing the drugmakers' bid for a second chance to disqualify Connecticut's former assistant attorney general from an antitrust case was not qualified for an interlocutory appeal.

  • April 22, 2026

    4 Firms Build Amneal's Up To $1.1B Kashiv Biosimilars Buy

    Biopharmaceutical company Amneal Pharmaceuticals Inc. on Wednesday unveiled plans to acquire biosimilars-focused Kashiv BioSciences LLC in a deal worth up to $1.1 billion that was built by four law firms.

  • April 22, 2026

    Chancery Sends Masimo Ex-CEO Pay Fight To California

    The Delaware Chancery Court sided with former Masimo Corp. CEO Joe E. Kiani in his fight with the global medical technology company, dismissing the company's lawsuit over a disputed $450 million severance package and ruling that the case must proceed in California, not Delaware.

  • April 21, 2026

    Armistice Capital Head Calls COVID Stock Rise 'Fun,' 'Lucky'

    Armistice Capital's founder defended his hedge fund Tuesday from claims it pump-and-dumped $250 million in Vaxart stock during the COVID-19 pandemic, telling a California federal jury that he and his fund got "lucky" and that the stock's rapid surge was "fun."

  • April 21, 2026

    Merck Beats Minn. Hockey Player's Talc Mesothelioma Claims

    A Chicago jury has found Merck & Co. not liable for a hockey player's mesothelioma allegedly caused by the Dr. Scholl's talc foot powder he used regularly for years.

  • April 21, 2026

    Biotech Co. Investors Clash Over 'Self-Dealing' Claim

    Attorneys for a biopharmaceutical and technology company stockholder and a group of venture investors sharply disagreed Tuesday over whether a financing deal was a lifeline for a struggling company or a self-serving maneuver that enriched insiders, as they argued a motion to dismiss the derivative suit in the Delaware Chancery Court.

  • April 21, 2026

    Congress Rallies More For Bills On Copyrights Than Patents

    There have been more intellectual property bills floated in Congress that are supportive of copyright rights than patent rights, according to a new report looking at how lawmakers treat the IP system.

  • April 21, 2026

    Amgen Faces ERISA Suit Over Health Plan Tobacco Surcharge

    A former Amgen Inc. employee filed a proposed class action in California federal court Tuesday alleging the biotech company discriminatorily imposes an "egregiously high" $150-a-month surcharge on employees who use tobacco products, while failing to adequately notify them of reasonable pathways to avoid the fees, in violation of federal benefits law.

  • April 21, 2026

    Pfizer, Dexcel Take 2 Patents Off Table For Bench Trial

    Drugmaker Pfizer and an Israeli competitor that is seeking to create a generic version of a Pfizer heart medication said Tuesday they have reached an agreement to remove two asserted patents from a trial set to start next week.

  • April 21, 2026

    Fed. Circ. Keeps Banner Witcoff And Saiber Off Patent Case

    The Federal Circuit kept intact the disqualification of two law firms from a patent ownership fight on Tuesday, saying it had not been shown a district judge made a clear error in removing them.

  • April 21, 2026

    Pot Management Co. Says It's Allowed Biz Tax Deduction

    A California-based management company linked to cannabis operations is challenging the IRS over a $4.2 million tax bill, according to a U.S. Tax Court petition, arguing that the company does not traffic in controlled substances that would otherwise bar it from claiming business deductions.

  • April 21, 2026

    Squires Stands By Ending Skincare IPR Over ITC Overlap

    U.S. Patent and Trademark Office Director John Squires has shot down Sinclair Pharma Ltd.'s request to revive its challenge to Hydrafacial LLC's skin treatment patent, which the director had terminated based on related proceedings at the U.S. International Trade Commission.

Expert Analysis

  • Series

    Fly-Fishing Makes Me A Better Lawyer

    Author Photo

    Much like skilled attorneys, the best anglers prize preparation, presentation and patience while respecting their adversaries — both human and trout, says Rob Braverman at Braverman Greenspun.

  • 4 Ways GCs Can Manage Growing Service Of Process Volume

    Author Photo

    As automation and arbitration increase the volume of legal filings, in-house counsel must build scalable service of process systems that strengthen corporate governance and manage risk in real time, says Paul Mathews at Corporation Service Co.

  • Series

    The Law Firm Merger Diaries: Forming Measurable Ties

    Author Photo

    Relationship-building should begin as early as possible in a law firm merger, as intentional pathways to bringing people together drive collaboration, positive client response, engagements and growth, says Amie Colby at Troutman.

  • AG Watch: Va. Insulin Price Probe Signals Rising Scrutiny

    Author Photo

    Virginia Attorney General Jason Miyares' recent investigation into insulin manufacturers and pharmacy benefit managers for allegedly colluding to artificially inflate insulin prices reflects a broader trend to leverage consumer protection authority in high-impact healthcare matters, and the upcoming leadership change is unlikely to diminish scrutiny in this area, says Chuck Slemp at Cozen O'Connor.

  • FDA's AI Deployment Brings New Potential And Risks

    Author Photo

    The U.S. Food and Drug Administration's recent announcement about making agentic artificial intelligence tools available to agency employees may portend accelerated regulatory timelines and lower costs for drug companies and consumers, but potential errors and biases will necessitate additional safeguards, says Angela Silva at Lewis Brisbois.

  • 3 Key Takeaways From Planned Rescheduling Of Cannabis

    Author Photo

    An executive order reviving cannabis rescheduling represents a monumental change for the industry and, while the substance will remain illegal at the federal level, introduces several benefits, including improving state-legal cannabis operators' tax treatment, lowering the industry's legal risk profile, and leaving state-regulated markets largely intact, say attorneys at Dentons.

  • 6 Issues That May Follow The 340B Rebate Pilot Challenge

    Author Photo

    Though the Health Resources and Services Administration withdrew a pending case to reconsider the controversial 340B rebate pilot program, a number of crucial considerations remain, including the likelihood of a rework and questions about what that rework might look like, say attorneys at Spencer Fane.

  • 5 E-Discovery Predictions For 2026 And Beyond

    Author Photo

    2026 will likely be shaped by issues ranging from artificial intelligence regulatory turbulence to potential evidence rule changes, and e-discovery professionals will need to understand how to effectively guide the responsible and defensible adoption of emerging tools, while also ensuring effective safeguards, say attorneys at Littler.

  • Streamlining Product Liability MDLs With AI And Rule 16.1

    Author Photo

    With newly effective Rule 16.1 of the Federal Rules of Civil Procedure providing enhanced guidance on multidistrict litigation and the sophistication of artificial intelligence continuing to advance, parties have the opportunity to better confront the significant data challenges presented by product liability MDLs, say attorneys at Hollingsworth.

  • Business Considerations Amid Hemp Product Policy Change

    Author Photo

    With the passage of a bill fundamentally narrowing the federal definition of "hemp," there are practical and business considerations that brands, manufacturers and other parties should heed over the next year, including operational strategies, evaluating contract and counterparty risk, and tax implications, say attorneys at Foley Hoag.

  • Series

    Judges On AI: How Courts Can Boost Access To Justice

    Author Photo

    Arizona Court of Appeals Judge Samuel A. Thumma writes that generative artificial intelligence tools offer a profound opportunity to enhance access to justice and engender public confidence in courts’ use of technology, and judges can seize this opportunity in five key ways.

  • Fed. Circ. In November: Looking For Patent 'Blaze Marks'

    Author Photo

    The Federal Circuit's recent decision in Duke v. Sandoz serves as a warning that when patentees craft claims, they must provide adequate "blaze marks" that direct a skilled artisan to the specific claimed invention, and not just the individual claimed elements in isolation, say attorneys at Knobbe Martens.

  • 2025's Most Notable State AG Activity By The Numbers

    Author Photo

    State attorneys general were active in 2025, working across party lines to address federal regulatory gaps in artificial intelligence, take action on consumer protection issues, continue antitrust enforcement and announce large settlements on behalf of their citizens, say attorneys at Jenner & Block.

  • Opinion

    The Case For Emulating, Not Dividing, The Ninth Circuit

    Author Photo

    Champions for improved judicial administration should reject the unfounded criticisms driving recent Senate proposals to divide the Ninth Circuit and instead seek to replicate the court's unique strengths and successes, says Ninth Circuit Judge J. Clifford Wallace.

  • How Rule 16.1 Streamlines And Validates Mass Tort Litigation

    Author Photo

    The new Rule 16.1 of the Federal Rules of Civil Procedure not only serves a practical purpose by endorsing early, structured case management and dispositive motion practice in multidistrict litigation, but also explicitly affirms the importance of MDL practice in the justice system, says Rocco Strangio at Milestone.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.